- Home
- PEGA vs JAZZ Comparison
PEGA vs JAZZ Comparison
Compare PEGA & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEGA
- JAZZ
- Stock Information
- Founded
- PEGA 1983
- JAZZ 2003
- Country
- PEGA United States
- JAZZ Ireland
- Employees
- PEGA N/A
- JAZZ N/A
- Industry
- PEGA EDP Services
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- PEGA Technology
- JAZZ Health Care
- Exchange
- PEGA Nasdaq
- JAZZ Nasdaq
- Market Cap
- PEGA 9.3B
- JAZZ 8.1B
- IPO Year
- PEGA 1996
- JAZZ 2007
- Fundamental
- Price
- PEGA $77.89
- JAZZ $136.01
- Analyst Decision
- PEGA Buy
- JAZZ Strong Buy
- Analyst Count
- PEGA 12
- JAZZ 14
- Target Price
- PEGA $100.17
- JAZZ $177.50
- AVG Volume (30 Days)
- PEGA 1.1M
- JAZZ 688.4K
- Earning Date
- PEGA 02-12-2025
- JAZZ 02-25-2025
- Dividend Yield
- PEGA 0.15%
- JAZZ N/A
- EPS Growth
- PEGA 50.76
- JAZZ 458.10
- EPS
- PEGA 1.11
- JAZZ 7.04
- Revenue
- PEGA $1,497,180,000.00
- JAZZ $3,992,712,000.00
- Revenue This Year
- PEGA $7.67
- JAZZ $7.53
- Revenue Next Year
- PEGA $7.57
- JAZZ $6.94
- P/E Ratio
- PEGA $70.44
- JAZZ $19.42
- Revenue Growth
- PEGA 4.51
- JAZZ 5.23
- 52 Week Low
- PEGA $54.55
- JAZZ $99.06
- 52 Week High
- PEGA $113.67
- JAZZ $138.27
- Technical
- Relative Strength Index (RSI)
- PEGA 24.39
- JAZZ 68.46
- Support Level
- PEGA $81.86
- JAZZ $134.56
- Resistance Level
- PEGA $86.58
- JAZZ $138.27
- Average True Range (ATR)
- PEGA 4.00
- JAZZ 3.56
- MACD
- PEGA -3.36
- JAZZ 1.17
- Stochastic Oscillator
- PEGA 0.44
- JAZZ 88.20
About PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management, or BPM, with customer relationship management, or CRM, applications. The company focuses on enterprise-size customers, specifically within the financial, insurance, and healthcare fields.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.